It’s all very well to gaze longingly at the Covid deaths and dream of the untold riches awaiting MSB shareholders if only stems could be released on the unsuspecting public.
But, the fly in the ointment of this pipe dream, is the fact MSB had a partner interested in developing the treatment who pulled out.
So, the inescapable conclusion is Novartis looked at the data and concluded it either it didn’t work very well, was too hard to manufacture, was too expensive, or a combination of all three.
Or, perhaps they know there will be better cheaper alternatives being developed at warp speed.
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-226
-
- There are more pages in this discussion • 680 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |